Skip to main content

Advertisement

Table 4 Failure rates at Day 28 after PCR adjustment in the studies in Boende and Kabalo

From: Varying efficacy of artesunate+amodiaquine and artesunate+sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in-vivo studies

Outcome
N
Boende Kabalo
SP
76
AQ
66
AS+SP
61
AS+AQ
58
SP
48
AS+SP
49
AS+AQ
52
ETF, n (%) 2 (2.6) 0 0 0 8 (16.7) 0 0
LCF, n (%) 16 (21.0) 10 (15.1) 13 (21.3) 8 (13.8) 3 (6.3) 0 0
LPF, n (%) 1 (19.7) 7 (10.6) 7 (11.5) 3 (5.2) 0 0 0
Overall failure rate1
% [95% CI]
35.9
[27.0–46.7]
18.3
[11.6–28.1]
24.6
[16.6–35.5]
15.1
[8.6–25.7]
19.6
[11.4–32.7]
0
[0–5.8]2
0
[0–6.2]2
  1. WHO 2001 outcome definitions used.
  2. ETF: early treatment failure; LFU: lost to follow-up; LCF: late clinical failure; LFP: late parasitological failure; ACPRA: adequate clinical and parasitological response
  3. 1 Estimated by Kaplan-Meier Survival Analysis, reinfections censored on day endpoint classified. Patients with missing or unresolved PCR results censored on last day seen with negative malaria smear result.
  4. 2 One sided CI for a proportion calculated (Wilson method)